Search clinical trials for: Atripla

Total 57 results

Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
University of California, San Francisco

Completed

Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

HIV Infections | Adherence
Merck Sharp & Dohme LLC

Completed

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)

Human Immunodeficiency Virus (HIV)
University of Nebraska
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

HIV | Contraception

Uganda
University of Nebraska
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

HIV | Contraception

Uganda
Rush University Medical Center
Gilead Sciences; University of Chicago; University of Illinois at Chicago; Abbott; Ruth M. Rothstein CORE Center

Terminated

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Acquired Immune Deficiency Syndrome

United States
Professor Francois Venter

Completed

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE)

HIV-1 Infection

South Africa
University of Alberta
University of British Columbia; Gilead Sciences

Terminated

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

HIV-1-infection

Canada
Fred Hutchinson Cancer Center
National Institute on Drug Abuse (NIDA); Asociación Civil Impacta Salud y Educación... and other collaborators

Completed

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (SABES?)

HIV

Peru
Professor Francois Venter
University of Cape Town

Completed

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants (EpiTAF)

Tuberculosis | HIV-1-infection

South Africa
University of Maryland, Baltimore

Completed

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

HIV Infections

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (REMEMBER)

HIV Infection

Peru, Malawi, Uganda, South Africa, India, Haiti, Zambia, Zimbabwe, Brazil, Kenya
ANRS, Emerging Infectious Diseases

Completed

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (STATIS)

HIV-1 Infection

Vietnam, Cambodia, Côte D'Ivoire, Uganda
University of California, San Diego
Merck Sharp & Dohme LLC; Abbott; California HIV/AIDS Research Program

Completed

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

HIV Infections

United States
Yu-Jay Corp.

Completed

Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

HIV Infections

Taiwan
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma (REACT-KS)

Kaposi's Sarcoma | HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Uganda
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
Azienda Ospedaliera San Gerardo di Monza
Gilead Sciences

Completed

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (SWEAR)

Quality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/Anxiety

Italy
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
Gilead Sciences

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

HIV-1 Infection

France, United Kingdom, Spain, Belgium, Ireland
Washington University School of Medicine

Completed

LAAM-HAART PET Imaging

Healthy Volunteers

United States
Bayer

Completed

Interaction With HIV Antiretroviral Agents

HIV-DDI

United States
UMC Utrecht
Gilead Sciences

Completed

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning (ESCAPE)

HIV Associated Neurocognitive Disorder | Neurocognitive Decline

Netherlands
Tufts University

Completed

Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men (PERTH)

HIV Infections | HIV Infection | Cardiovascular Risk

United States
Community Research Initiative of New England
The Campbell Foundation

Completed

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

HIV Infections

United States
St Stephens Aids Trust
Gilead Sciences

Completed

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

HIV

United Kingdom
Midtown Medical Center, Tampa, FL
Gilead Sciences

Completed

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

HIV | Sleep Disorders | AIDS
St Stephens Aids Trust

Completed

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

HIV

United Kingdom
St Stephens Aids Trust
United States Agency for International Development (USAID); Mylan Inc.

Unknown

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

HIV

Uganda, United Kingdom
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences

Completed

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

HIV-1

Spain
Community Research Initiative of New England
Merck Sharp & Dohme LLC

Withdrawn

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

HIV Infections | Acquired Immune Deficiency Syndrome
Sheba Medical Center

Terminated

Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera (DeepSwitch)

HIV

Israel
University of Hawaii
Gilead Sciences

Unknown

Sleep and Cognition After Atripla to Stribild Switch

HIV

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States, Puerto Rico
Anna Cruceta

Completed

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (A-TRI-WEEK)

HIV

Spain
University of Minnesota
Merck Sharp & Dohme LLC

Withdrawn

Raltegravir Activity In Lymphoid Tissues

HIV Infections | HIV Infection

United States
Rush University Medical Center
Merck Sharp & Dohme LLC

Withdrawn

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women (ICE-002)

HIV-1 Infections

United States
Sanofi

Completed

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Tuberculosis

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Human Immunodeficiency Virus

United States
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
Tufts University
Christian Medical College, Vellore, India

Completed

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

HIV

India
St Stephens Aids Trust
ViiV Healthcare

Unknown

Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

HIV

United Kingdom
Gilead Sciences

Completed

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Hepatitis C | HIV

Puerto Rico
French National Agency for Research on AIDS and...
Gilead Sciences; Abbott

Completed

Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (ANRS 140 DREAM)

HIV Infections

France
Gilead Sciences

Completed

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV Infections | HIV

United States
University of California, San Diego
National Institute of Mental Health (NIMH); National Institutes of Health (NIH)

Completed

Clinical Trial of CNS-targeted HAART (CIT2)

HIV Infections

United States
Indiana University
Merck Sharp & Dohme LLC

Completed

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

HIV

United States

3

Subscribe